[blockquote align=””]
Previous research suggests immunomodulatory therapies, such as intravenous immunoglobulin (IVIG), may lead to rapid and sustained symptom improvement in patients with PANDAS.
Conclusion: Between-group differences were smaller than anticipated, and the double-blind comparison failed to demonstrate superiority of IVIG over placebo.[/blockquote]
[button style=”arrow-right” title=”Read the abstract here” url=”http://www.jaacap.com/article/S0890-8567(16)31158-3/fulltext”]
